Johnson & Johnson To Acquire Ollin Biosciences In $2.2 Bln Deal
(RTTNews) - Healthcare company Johnson & Johnson (JNJ) announced on Monday that it has agreed to acquire clinical-stage biopharmaceutical company Ollin Biosciences for $2.2 billion upfront, expanding its ophthalmology pipeline.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.